[go: up one dir, main page]

PE20030867A1 - Derivados de quinazolinona - Google Patents

Derivados de quinazolinona

Info

Publication number
PE20030867A1
PE20030867A1 PE2003000129A PE2003000129A PE20030867A1 PE 20030867 A1 PE20030867 A1 PE 20030867A1 PE 2003000129 A PE2003000129 A PE 2003000129A PE 2003000129 A PE2003000129 A PE 2003000129A PE 20030867 A1 PE20030867 A1 PE 20030867A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
alkenyl
methyl
refers
Prior art date
Application number
PE2003000129A
Other languages
English (en)
Inventor
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030867A1 publication Critical patent/PE20030867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINAZOLINA DE FORMULA I DONDE: R1, R2, R3, R4, R5 SON H, HALOGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ALCOXILO-ALQUILO, HIDROXIALCOXILO, HIDROXILO, ENTRE OTROS; R1 Y R2 O R2 Y R3 JUNTO AL CARBONO FORMAN UN GRUPO CARBOCICLICO AROMATICO, ALIFATICO DE 5-10 MIEMBROS; R6 ES CH2-O-CO-NR12R13, CH2-X-CO-R14, ALQUILO, HIDROXIALQUILO; R7, R8, R9 SON ALQUILO; R10 Y R11 SON H, ALQUILO, ALQUENILO; CICLOALQUILO, ENTRE OTROS; R12 Y R13 SON H, ALQUILO, ALQUENILO, CICLOALQUILO, CICLOALQUILO-ALQUILO; R14 ES NH, ALQUILO-NH, ALQUENILO-NH, CICLOALQUILO-NH, CICLOALQUILO-ALQUILO-NH; X ES O, S; CUANDO R1 ES HALOGENO, METILO, ETILO, METOXILO, TRIFLUOROMETILO, H; R2, R3, R4 SON H, METILO, METOXILO; R5 ES H, METILO; R12 NO ES H, ALQUILO, ALQUENILO, ALQUILENO-SOR10. SON COMPUESTOS PREFERIDOS ETILESTER DEL ACIDO 2-ETILCARBAMOILOXIMETIL-5,7-DIMETIL-3-(2-METILSULFAMOIL-FENIL)-4-OXO-3,4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO; ETILESTER DEL ACIDO 2-(2-HIDROXI-ETILCARBAMOILOXIMETIL)-5,7-DIMETIL-3-(2-METILSULFAMOIL-FENIL)-4-OXO-3,4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO. TAMBIEN SE REFIERE A UN PROCESO PARA LA PRODUCCION. LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR CANNABINOIDE Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DESORDENES OCULARES COMO GLAUCOMA, GLAUCOMA POR TENSION NORMAL, ENFERMEDADES NEURODEGENERATIVAS DE LA RETINA Y DEL NERVIO OPTICO. TAMBIEN SE REFIERE A UNA COMBINACION QUE EMPLEA ADEMAS UN FARMACO UTIL PARA EL DOLOR CRONICO, OSTEOARTRITIS, ARTRITIS REUMATOIDE, TENO-SINOVITIS, GOTA
PE2003000129A 2002-02-06 2003-02-04 Derivados de quinazolinona PE20030867A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound

Publications (1)

Publication Number Publication Date
PE20030867A1 true PE20030867A1 (es) 2003-12-04

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000129A PE20030867A1 (es) 2002-02-06 2003-02-04 Derivados de quinazolinona

Country Status (21)

Country Link
US (2) US20050085493A1 (es)
EP (2) EP2319839A1 (es)
JP (2) JP4428479B2 (es)
KR (1) KR100954626B1 (es)
CN (1) CN100579968C (es)
AR (1) AR038483A1 (es)
AT (1) ATE551329T1 (es)
AU (1) AU2003210212A1 (es)
BR (1) BR0307461A (es)
CA (1) CA2471974C (es)
CO (1) CO5601021A2 (es)
EC (1) ECSP045219A (es)
ES (1) ES2384967T3 (es)
MX (1) MXPA04007641A (es)
MY (1) MY143958A (es)
NO (1) NO328305B1 (es)
NZ (1) NZ571615A (es)
PE (1) PE20030867A1 (es)
PL (1) PL370657A1 (es)
TW (1) TW200306839A (es)
WO (1) WO2003066603A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761453B2 (en) 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
CA2544191A1 (en) 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
EP1904068A1 (en) * 2005-07-11 2008-04-02 N.V. Organon Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
TW201348235A (zh) 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (es) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
AU4246793A (en) * 1992-05-13 1993-12-13 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2005522439A (ja) 2005-07-28
NO328305B1 (no) 2010-01-25
AU2003210212A1 (en) 2003-09-02
CA2471974C (en) 2011-11-22
EP2319839A1 (en) 2011-05-11
US20070265285A1 (en) 2007-11-15
US8552015B2 (en) 2013-10-08
TW200306839A (en) 2003-12-01
AR038483A1 (es) 2005-01-19
KR20040083501A (ko) 2004-10-02
CA2471974A1 (en) 2003-08-14
JP4428479B2 (ja) 2010-03-10
NZ571615A (en) 2010-01-29
ES2384967T3 (es) 2012-07-16
KR100954626B1 (ko) 2010-04-27
JP2009149658A (ja) 2009-07-09
CO5601021A2 (es) 2006-01-31
ECSP045219A (es) 2004-09-28
US20050085493A1 (en) 2005-04-21
MXPA04007641A (es) 2004-11-10
BR0307461A (pt) 2004-11-09
HK1079518A1 (zh) 2006-04-07
NO20043580L (no) 2004-09-21
NO20043580D0 (no) 2004-08-27
CN1628104A (zh) 2005-06-15
EP1472234A1 (en) 2004-11-03
CN100579968C (zh) 2010-01-13
PL370657A1 (en) 2005-05-30
WO2003066603A1 (en) 2003-08-14
MY143958A (en) 2011-07-29
ATE551329T1 (de) 2012-04-15
EP1472234B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
PE20030867A1 (es) Derivados de quinazolinona
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
RU2012141706A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
ES2094843T3 (es) Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos.
RU2008101923A (ru) Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
RU98114683A (ru) Производные 5-н-тиазол[3,2-a]пиримидина
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
KR930000490A (ko) 치료용 제제
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
IL299831B1 (en) Derivatives of substituted (isoxazolidine-2-yl)pyrimidine-4-yl-amino, and pharmaceutical composition comprising same as effective component
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
UY25095A1 (es) Derivados de la 5h-tiazolo (3,2-a) pirimidina
RU2009136592A (ru) Терапевтические агенты
DK0518530T3 (da) Forbedringer af eller i forbindelse med excitatoriske aminosyrereceptorantagonister
AU2010257272A1 (en) Compositions and methods for treating cognitive disorders
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
PE20030714A1 (es) Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf
EA202190431A1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed